Published in Blood Weekly, February 15th, 2007
"This designation underscores the need for improved therapies in ALL, and supports our development strategy in areas of unmet medical need," commented Greg Berk, MD, senior vice president and chief medical officer. "Hana Biosciences is committed to the clinical development of Marqibo in ALL and other lymphoproliferative diseases."
In December...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-02-15)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.